2023-03-08 16:07:58 ET
- OPKO Health ( NASDAQ: OPK ) closed up 6.6% on Wednesday after signing a licensing deal with Merck to develop an Epstein-Barr virus vaccine together.
- The arrangement is between OPKO's ( OPK ) ModeX Therapeutics unit and Merck ( MRK ) for preclinical candidate MDX-2201.
- OPKO ( OPK ) will receive an upfront payment of $50M, as well as milestone payments of up to $872.5M , plus royalties.
- Read why Seeking Alpha contributor Harold Goldmeier says that OPKO ( OPK ) is a hold.
For further details see:
Why did OPKO Health stock jump today? Vaccine license deal with Merck